Johnson & Johnson has unveiled massive phase 3 survival data for its dual bispecific combination in earlier-line multiple ...

In a landmark moment for its oncology ambitions, GSK has secured FDA approval for Jideytro (zidesamtinib) as the first ...

The FDA has called out Sanofi’s promotion of respiratory syncytial virus (RSV) antibody Beyfortus in a new untitled letter, ...

While the White House focused its initial Section 232 pharmaceutical tariffs on branded drugs, generics makers—who supply the ...

Aiming to bolster ivonescimab’s case ahead of a key FDA decision, Summit Therapeutics has provided updated overall survival ...

A U.K. marketing watchdog has reprimanded Sanofi for using “a highly misleading interpretation of data” to make disparaging ...

Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become the first drug to specifically ...

Novo Nordisk has accused Eli Lilly of running ad campaigns containing “deliberately false” messages that mislead the public ...

Amgen has agreed to a $74 million settlement with investors who allege that the company hid a massive U.S. tax bill from the ...

Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has ...

From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites ...

Novartis' CEO remains unfazed by the threat of a newly approved oral PCSK9 inhibitor in Merck & Co.’s Lipfendra, doubling ...